Edgar Cheng

831 total citations
31 papers, 620 citations indexed

About

Edgar Cheng is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Edgar Cheng has authored 31 papers receiving a total of 620 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 10 papers in Surgery and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Edgar Cheng's work include Cancer Treatment and Pharmacology (8 papers), Testicular diseases and treatments (6 papers) and Lung Cancer Research Studies (6 papers). Edgar Cheng is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Testicular diseases and treatments (6 papers) and Lung Cancer Research Studies (6 papers). Edgar Cheng collaborates with scholars based in United States and Russia. Edgar Cheng's co-authors include Esteban Cvitkovic, Robert B. Golbey, John H. Raaf, Carlos Urmacher, Man H. Shiu, Davor Vugrin, Willet F. Whitmore, Gordon B. Magill, Robert E. Wittes and Robert Golbey and has published in prestigious journals such as Cancer, CHEST Journal and Investigational New Drugs.

In The Last Decade

Edgar Cheng

31 papers receiving 561 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edgar Cheng United States 14 295 259 196 100 97 31 620
Leonard Giannone United States 10 225 0.8× 55 0.2× 175 0.9× 56 0.6× 59 0.6× 14 416
Jong Sun Choi South Korea 14 178 0.6× 67 0.3× 108 0.6× 48 0.5× 139 1.4× 24 481
Christopher G. Sakellis United States 10 194 0.7× 35 0.1× 58 0.3× 33 0.3× 29 0.3× 21 322
Julieta E. Barroeta United States 10 90 0.3× 138 0.5× 80 0.4× 20 0.2× 59 0.6× 36 429
Paolo Del Fiore Italy 13 333 1.1× 59 0.2× 124 0.6× 15 0.1× 103 1.1× 78 539
Elihu J. Ledesma United States 11 437 1.5× 271 1.0× 184 0.9× 3 0.0× 54 0.6× 19 585
Soyeon An South Korea 14 323 1.1× 108 0.4× 67 0.3× 119 1.2× 69 0.7× 42 516
P Dallera Italy 7 573 1.9× 217 0.8× 327 1.7× 5 0.1× 70 0.7× 12 836
J. L. G. Blaauwgeers Netherlands 14 190 0.6× 195 0.8× 175 0.9× 221 2.2× 57 0.6× 31 658
Katsuyoshi Tabuse Japan 15 211 0.7× 402 1.6× 250 1.3× 9 0.1× 48 0.5× 71 793

Countries citing papers authored by Edgar Cheng

Since Specialization
Citations

This map shows the geographic impact of Edgar Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edgar Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edgar Cheng more than expected).

Fields of papers citing papers by Edgar Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edgar Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edgar Cheng. The network helps show where Edgar Cheng may publish in the future.

Co-authorship network of co-authors of Edgar Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Edgar Cheng. A scholar is included among the top collaborators of Edgar Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edgar Cheng. Edgar Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Magill, Gordon B., Ephraim S. Casper, Edgar Cheng, et al.. (1992). Oral piritrexim — A phase II study in patients with advanced soft tissue sarcoma. Investigational New Drugs. 10(2). 97–98. 13 indexed citations
2.
Frame, James D., et al.. (1988). A Phase II Trial of Streptozotocin and Adriamycin in Advanced APUD Tumors. American Journal of Clinical Oncology. 11(4). 490–495. 27 indexed citations
3.
Sternberg, Cora N., et al.. (1988). Etoposide (VP-16) in the Treatment of Advanced Adenocarcinoma of the Pancreas. American Journal of Clinical Oncology. 11(2). 172–173. 4 indexed citations
4.
Sternberg, Cora N., Gordon B. Magill, Edgar Cheng, & Phyllis Hollander. (1988). Phase II Trial of Menogarol in the Treatment of Advanced Adenocarcinoma of the Pancreas. American Journal of Clinical Oncology. 11(2). 174–176. 4 indexed citations
5.
Kelsen, David P., et al.. (1987). Phase II trial of etoposide in APUD tumors.. PubMed. 71(3). 305–7. 17 indexed citations
6.
Mittelman, A, et al.. (1987). Phase II trial of idarubicin in patients with pancreatic cancer.. PubMed. 71(6). 657–8. 2 indexed citations
7.
Sternberg, Cora N., et al.. (1987). Evaluation of New Anticancer Agents Against Human Pancreatic Carcinomas in Nude Mice. American Journal of Clinical Oncology. 10(3). 219–221. 8 indexed citations
8.
Tauer, Kurt W., Nancy E. Kemeny, Edgar Cheng, Phyllis Hollander, & Nancy L. Geller. (1986). Phase II trial of N-methylformamide in patients with advanced colorectal carcinoma.. PubMed. 70(6). 813–4. 4 indexed citations
9.
Raaf, John H., et al.. (1986). Trabecular (merkel cell) carcinoma of the skin. Treatment of primary, recurrent, and metastatic disease. Cancer. 57(1). 178–182. 121 indexed citations
10.
Kelsen, D. P., et al.. (1985). Adenocarcinoma of unknown primary origin: treatment with vindesine and doxorubicin.. PubMed. 69(6). 591–4. 16 indexed citations
11.
Einzig, Avi I., D. P. Kelsen, Edgar Cheng, et al.. (1985). Phase II trial of carboplatin in patients with adenocarcinomas of the upper gastrointestinal tract.. PubMed. 69(12). 1453–4. 13 indexed citations
12.
Kemeny, N. E., et al.. (1984). Phase II trial of 4-demethoxydaunorubicin in advanced colorectal carcinoma.. PubMed. 68(4). 689–90. 8 indexed citations
13.
Kelsen, David P., R. Gralla, Edgar Cheng, & Nael Martini. (1983). Vindesine in the treatment of malignant mesothelioma: a phase II study.. PubMed. 67(9). 821–2. 23 indexed citations
14.
Sternberg, Cora N., Gordon B. Magill, Peter P. Sordillo, Edgar Cheng, & Violante E. Currie. (1983). Phase II evaluation of m-AMSA (4'-(9-acridinylamino)-methane-sulfon-m-anisidide) in patients with adenocarcinoma of the pancreas. American Journal of Clinical Oncology. 6(4). 459–462. 3 indexed citations
15.
Kelsen, David P., John L. Hoffman, Nancy W. Alcock, et al.. (1982). Pharmacokinetics of cisplatin regional hepatic infusions. American Journal of Clinical Oncology. 5(2). 173–178. 22 indexed citations
16.
Kelsen, David P., R. Gralla, Mark Stoopler, et al.. (1982). Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer.. PubMed. 66(2). 247–51. 17 indexed citations
17.
Brenner, Joseph, Gordon B. Magill, Peter P. Sordillo, Edgar Cheng, & A Yagoda. (1982). Phase II trial of cisplatin (CPDD) in previously treated patients with advanced soft tissue sarcoma. Cancer. 50(10). 2031–2033. 23 indexed citations
18.
Cheng, Edgar, Charles W. Young, & R. Wittes. (1981). Phase II trial of vindesine in advanced head and neck cancer.. PubMed. 64(10-11). 1141–2. 4 indexed citations
19.
Reynolds, Thomas F., Davor Vugrin, Esteban Cvitkovic, et al.. (1981). VAB-3 combination chemotherapy of metastatic testicular cancer. Cancer. 48(4). 888–898. 57 indexed citations
20.
Schulman, Philip, Edgar Cheng, Esteban Cvitkovic, & Robert Golbey. (1979). Spontaneous Pneumothorax as a Result of Intensive Cytotoxic Chemotherapy. CHEST Journal. 75(2). 194–196. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leonard Giannone Breakdown of academic impact, for papers by Jong Sun Choi Breakdown of academic impact, for papers by Christopher G. Sakellis Breakdown of academic impact, for papers by Julieta E. Barroeta Breakdown of academic impact, for papers by Paolo Del Fiore Breakdown of academic impact, for papers by Elihu J. Ledesma Breakdown of academic impact, for papers by Soyeon An Breakdown of academic impact, for papers by P Dallera Breakdown of academic impact, for papers by J. L. G. Blaauwgeers Breakdown of academic impact, for papers by Katsuyoshi Tabuse
Rankless by CCL
2026